Torii Pharmaceutical Co., Ltd. authorizes a Buyback Plan.

Published on 06/05/2025 at 23:00

S&P Capital IQ

Torii Pharmaceutical Co., Ltd.

0.00%

Japan Tobacco Inc.

-0.85%

The Board of Directors of Torii Pharmaceutical Co., Ltd. has authorized a buyback plan on May 7, 2025.

Latest news about Torii Pharmaceutical Co., Ltd.

Torii Pharmaceutical Co Ltd says it will retire treasury shares worth 2.39% of outstanding stock on Aug 29	07-10	RE
Verrica Pharmaceuticals Announces Amendment to Collaboration and License Agreement with Torii Pharmaceutical to Launch Global Pivotal Phase 3 Clinical Trial to Study YCANTH for the Treatment of Common Warts	07-01	CI
Torii Pharmaceutical Co., Ltd.(TSE:4551) dropped from S&P Global BMI Index	06-30	CI
Shionogi Completes Tender Offer for Torii Pharmaceutical, Acquiring 39% Stake	06-19	MT
Shionogi & Co., Ltd. completed the acquisition of 44.1% stake in Torii Pharmaceutical Co., Ltd. from group of sellers.	06-17	CI
Japan's Nikkei ends higher; NTT Data surges on takeover report	05-08	RE
Japan's Nikkei rises; NTT Data set to surge on takeover report	05-08	RE
Shionogi to Acquire Japan Tobacco's Pharma Business, Take Full Control of Torii Pharmaceutical	05-07	MT
Deals of the day-Mergers and acquisitions	05-07	RE
Torii Pharmaceutical Co., Ltd. announces an Equity Buyback for 15,398,800 shares, representing 54.78% for ¥70,341.72 million.	05-07	CI
Deals of the day-Mergers and acquisitions	05-07	RE
Drugmaker Shionogi to buy Japan Tobacco's unit Torii Pharmaceutical for $1 billion	05-07	RE
Drugmaker Shionogi to buy Japan Tobacco's unit Torii Pharmaceutical for $1 billion	05-07	RE
Shionogi & Co: To Launch Tender Offer For Torii Pharmaceutical Shares At 6,350 Yen Per Share	05-07	RE
Japan's Shionogi to buy Torii Pharmaceutical for $1 billion, Nikkei says	05-07	RE
Shionogi To Buy Torii Pharmaceutical For About 150 Billion Yen, Nikkei Says	05-07	RE
Torii Pharmaceutical Co., Ltd. authorizes a Buyback Plan.	05-06	CI
Shionogi & Co., Ltd. proposed to acquire 44.1% stake in Torii Pharmaceutical Co., Ltd. from group of sellers for ¥80.7 billion.	05-06	CI
Verrica Pharmaceuticals' Partner Torii Seeks Japan Approval for Skin Infection Treatment	12-06	MT
Torii Pharmaceutical Files New Drug Application of TO-208 the Treatment of Molluscum Contagiosum in Japan	12-06	CI
Verrica Pharmaceuticals Amends Licensing Agreement With Torii Pharmaceutical for Phase 3 Trial of Ycanth	15/05/24	MT
Verrica Pharmaceuticals Inc. Announces Amendment to Collaboration and License Agreement with Torii Pharmaceutical Co. Ltd. to Fund Global Pivotal Phase 3 Clinical Trial to Study Ycanth for the Treatment of Common Warts	15/05/24	CI
Torii Pharmaceutical Co., Ltd Announces Voting Results	29/03/24	CI
LIM Advisors Partially Withdraws Shareholder Proposal	13/02/24	CI
Torii Pharmaceuticals Opposes Shareholder Proposal	09/02/24	CI